• 1
    Creutzig U,Zimmermann M,Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005; 19: 20302042.
  • 2
    Gibson BE,Wheatley K,Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005; 19: 21302138.
  • 3
    Lie SO,Abrahamsson J,Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group–report of 3 consecutive trials. Leukemia. 2005; 19: 20902100.
  • 4
    Creutzig U,Zimmermann M,Reinhardt D,Dworzak M,Stary J,Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004; 22: 43844393.
  • 5
    Riley LC,Hann IM,Wheatley K,Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999; 106: 436444.
  • 6
    Rubnitz JE,Lensing S,Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004; 101: 16771684.
  • 7
    Husain E,Whitehead S,Castell A,Thomas EE,Speert DP. Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr Infect Dis J. 2005; 24: 563566.
  • 8
    Gamis AS,Howells WB,DeSwarte-Wallace J,Feusner JH,Buckley JD,Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group Study CCG-2891. J Clin Oncol. 2000; 18: 18451855.
  • 9
    Sotiropoulos SV,Jackson MA,Woods GM,Hicks RA,Cullen J,Freeman AI. Alpha-streptococcal septicemia in leukemic children treated with continuous or large dosage intermittent cytosine arabinoside. Pediatr Infect Dis J. 1989; 8: 755758.
  • 10
    Weisman SJ,Scoopo FJ,Johnson GM,Altman AJ,Quinn JJ. Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol. 1990; 8: 453459.
  • 11
    Okamoto Y,Ribeiro RC,Srivastava DK,Shenep JL,Pui CH,Razzouk BI. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003; 25: 696703.
  • 12
    Sung L,Lange BJ,Gerbing RB,Alonzo TA,Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007; 110: 35323539.
  • 13
    Lehrnbecher T,Varwig D,Kaiser J,Reinhardt D,Klingebiel T,Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004; 18: 7277.
  • 14
    Grimwade D,Walker H,Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 15
    Rubnitz JE,Raimondi SC,Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002; 20: 23022309.
  • 16
    Raimondi SC,Chang MN,Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821. Blood. 1999; 94: 37073716.
  • 17
    Meshinchi S,Alonzo TA,Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006; 108: 36543661.
  • 18
    Soekarman D,von Lindern M,Daenen S, et al. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood. 1992; 79: 29902997.
  • 19
    Woods WG,Barnard DR,Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol. 2002; 20: 434440.
  • 20
    Garner JS,Jarvis WR,Emori TG,Horan TC,Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16: 128140. Erratum in: Am J Infect Control. 1988 16:177.
  • 21
    Diggle PJ,Liang KY,Zeger SL. Analysis of Longitudinal Data. New York, NY: Oxford; 1994.
  • 22
    Brunet AS,Ploton C,Galambrun C, et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006; 47: 765772.
  • 23
    Razonable RR,Litzow MR,Khaliq Y,Piper KE,Rouse MS,Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis. 2002; 34: 14691474.
  • 24
    Gafter-Gvili A,Fraser A,Paul M,Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005; 142: 979995.
  • 25
    Cullen M,Steven N,Billingham L, et al. Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005; 353: 988998.
  • 26
    Bucaneve G,Micozzi A,Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005; 353: 977987.
  • 27
    Lo N,Cullen M. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol. 2006; 24: 120125.
  • 28
    Padiglione AA,Wolfe R,Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother. 2003; 47: 24922498.